Urantide Conformation and Interaction with the Urotensin-II Receptor

被引:13
|
作者
Brancaccio, Diego [1 ]
Limatola, Antonio [1 ]
Campiglia, Pietro [2 ]
Gomez-Monterrey, Isabel [1 ]
Novellino, Ettore [1 ]
Grieco, Paolo [1 ]
Carotenuto, Alfonso [1 ]
机构
[1] Univ Naples Federico II, Dipartimento Farm, I-80131 Naples, Italy
[2] Univ Salerno, Dept Pharm, I-84100 Salerno, Italy
关键词
Atherosclerosis; Conformation by NMR; Docking studies; Therapeutic peptide; Urotensin-II; BINDING MODE; CRYSTAL-STRUCTURE; DICARBA-ANALOGS; ORPHAN RECEPTOR; MESSENGER-RNA; PEPTIDE; INSIGHT; IDENTIFICATION; LIGANDS; PROGRAM;
D O I
10.1002/ardp.201300269
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Urotensin II (U-II) is a disulfide bridged peptide hormone identified as the ligand of a G protein-coupled receptor. Human U-II (H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) has been described as the most potent vasoconstrictor compound identified to date. We have previously identified the compound termed urantide (H-Asp-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH), which is the most potent UT receptor (UTR) antagonist described to date. Urantide may have potential clinical value in the treatment of atherosclerosis. In the present study, we studied the conformational preferences of urantide in DPC micelles and developed a urantide/UTR interaction model. This model can help the design of novel peptides and small molecules as UTR antagonists.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 50 条
  • [1] Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP and urantide
    Boivin, S.
    Guilhaudis, L.
    Milazzo, I.
    Oulyadi, H.
    Davoust, D.
    Fournier, A.
    JOURNAL OF PEPTIDE SCIENCE, 2006, 12 : 193 - 193
  • [2] Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II
    Boivin, Stephane
    Segalas-Milazzo, Isabelle
    Guilhaudis, Laure
    Oulyadi, Hassan
    Fournier, Alain
    Dauoust, Daniel
    PEPTIDES, 2008, 29 (05) : 700 - 710
  • [3] Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide
    Boivin, Stephane
    Guilhaudis, Laure
    Milazzo, Isabelle
    Oulyadi, Hassan
    Davoust, Daniel
    Fournier, Alain
    BIOCHEMISTRY, 2006, 45 (19) : 5993 - 6002
  • [4] Urotensin-II receptor antagonists
    Carotenuto, A
    Griecio, P
    Rovero, P
    Novellino, E
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (03) : 267 - 275
  • [5] Urotensin-II receptor modulators
    Dhanak, D
    Neeb, MJ
    Douglas, SA
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 99 - 110
  • [6] Urotensin-II receptor antagonists
    Edwards, P
    DRUG DISCOVERY TODAY, 2006, 11 (3-4) : 181 - 181
  • [7] Atypical regulation of the urotensin-II receptor
    Onan, D
    Dinh, D
    Hannan, R
    Thomas, W
    FASEB JOURNAL, 2004, 18 (08): : C42 - C42
  • [8] A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects
    Benjamin D. Hunt
    Leong L. Ng
    David G. Lambert
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382 : 1 - 31
  • [9] Urotensin-II receptor peptide agonists
    Carotenuto, A
    Grieco, P
    Novellino, E
    Rovero, P
    MEDICINAL RESEARCH REVIEWS, 2004, 24 (05) : 577 - 588
  • [10] Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor
    Carotenuto, Alfonso
    Auriemma, Luigia
    Merlino, Francesco
    Yousif, Ali Munaim
    Marasco, Daniela
    Limatola, Antonio
    Campiglia, Pietro
    Gomez-Monterrey, Isabel
    Santicioli, Paolo
    Meini, Stefania
    Maggi, Carlo A.
    Novellino, Ettore
    Grieco, Paolo
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (14) : 5965 - 5974